For instance, ACE inhibitor [55], [56], [57], [58] and beta-blocker [59], [60], [61], [62] therapy after acute MI complicated by congestive heart failure or LV dysfunction has demonstrated a 15–20% relative risk reduction in mortality and cardiovascular morbidity within stable patients. The gene discussed is ACE; the disease is congestive heart failure.